Nicole Lamanna, M.D., reflects on the factors that influence her decision-making process while selecting an approved therapy or clinical trial for patients with chronic lymphocytic leukemia (CLL).
The optimal length of time to wait to initiate treatment for patients with chronic lymphocytic leukemia (CLL), as well as the length of time to remain on treatment, are described by Nicole Lamanna, M.D.
With regard to cytogenetic testing, molecular testing, and imaging, Nicole Lamanna, M.D., outlines what testing should be completed alongside a diagnosis of chronic lymphocytic leukemia (CLL).
The Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients aged 2 or older.
The Food and Drug Administration approved Asparlas (calaspargase pegol-mknl) as a component of a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia (ALL), according to the agency.
This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.
Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.
The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.